We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Copper Complex Halts Botulinum Neurotoxin Poisoning

By HospiMedica International staff writers
Posted on 12 Jun 2017
A new study describes how a readily available metal salt could provide a new therapy for Botulinum Neurotoxin type A (BoNT/A), the most common and deadly cause of human botulism.

Researchers at the Scripps Research Institute (TSRI; La Jolla, CA, USA), Boston University (MA, USA), and other institutions conducted a study that screened various triazole compounds against the BoNT/A light chain (LC) protease, a proteolytic enzyme that disrupts neuronal signaling to muscles. They found to their surprise that it was metal salts, and not the triazole compounds that showed marked inhibitory activity, and that copper cations in particular displayed noncompetitive inhibition of the LC, with mercury cations 10-fold more potent.

They then examined ligand-copper complexes in a cell-based model, and found that they too prevented BoNT/A cleavage of the endogenous protein substrate (SNAP-25) even at low μM concentrations. The researchers suggest that a bio-reductive mechanism caused an intracellular release of copper, which directly inhibited the BoNT/A protease. Further in-vivo experiments in rodents showed that copper (II) dithiocarbamate and bis(thiosemicarbazone) complexes could be used to treat the harmful effects of BoNT/A intoxication. The study was published on May 5, 2017, in JACS.

“Currently, botulism sufferers receive an anti-toxin medicine that can inactivate the toxin circulating in their system, thereby preventing further poisoning. However, the anti-toxin cannot reverse preexisting paralysis because the toxin acts inside cells,” said lead author Professor Kim Janda, PhD, of the TSRI department of chemistry. “Consequently, disease recovery can be slow, and paralysis may take weeks or months to wear off. This new therapy can readily enter cells where it can attack the etiological agent, a protease, which is responsible for paralysis seen from the neurotoxin.”

BoNT-A is probably best known as Botox, an injectable toxin commonly used to treat various movement disorders, such as focal dystonias, and in cosmetic treatments by paralyzing smooth muscles that cause wrinkles. It is also one of the most potent toxins on earth, and is classified as a potential bioterrorism threat, together with as Anthrax, Plague, Ebola, and other Category A priority pathogens.

Related Links:
Scripps Research Institute
Boston University
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Surgical Headlight
IsoTorch
New
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer

Channels

Surgical Techniques

view channel
Image: The novel approach combining MRI, fluid dynamics, and custom algorithms predicts brain cancer recurrence sites (photo courtesy of AdobeStock)

Novel Method Uses Interstitial Fluid Flow to Predict Where Brain Tumor Can Grow Next

Glioblastoma is one of the most aggressive brain cancers, with patients surviving on average only 15 months after diagnosis. Surgery and radiation can temporarily control the tumor, but the disease almost... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more